BREAKING: The average Anthropic, $ANT, employee will be worth $44 million after today's IPO, based on current indicated share price:
1. 7 Co-Founders: ~$20+ billion each
2. Several early employees: $1+ billion each
3. 598 employees: $100+ million each
4. 2,800 employees: $1+ million each
5. Total employee equity wealth: $232 billion
6. Employee stock option gains: $119 billion
San Francisco’s median single-family home sale price jumped +29% year over year to $2.39 million in October amid the IPO process.
This marks the largest jump in San Francisco's media home price since February 2018.
Thousands of new millionaires will be minted today.
Listen to Drs. Gordon Smith and Marcus V. Pinto, discuss his article on "Amyloid Neuropathies" in the October #PeripheralNerve and Motor Neuron Disorders issue. Episode available on all platforms or at https://t.co/4hkPmwIrDk @GordonSmithMD
There are many ways to state the second law of thermodynamics. Most break down somewhere.
Conjecture Institute Senior Scientist Chiara Marletto’s constructor theory version holds at every scale, from steam engines to single atoms. It needs no approximations and has no paradox.
The eyes may tell you which ataxia your patient has.
This outstanding practical review reminds us that specific oculomotor findings can be powerful diagnostic clues:
-Slow saccades → think SCA2
-Vertical supranuclear gaze palsy → think Niemann-Pick type C
-Bilateral VOR loss → think CANVAS
-"Bulging eyes" (pseudoproptosis) → think SCA3
Before the genetic report arrives, the bedside eye movement exam may already be pointing you in the right direction. https://t.co/bRSoWKPHia
Bayes' Theorem You Can See
A probability is a share of the dots. P(A) is the part of the box covered by circle A, and P(B given A) is the part of A that is also in B: the lens divided by A.
Slide the circles around and every number updates: apart, the lens is empty and both conditionals are 0; tuck B inside A and P(A given B) becomes 1.
The lens is the same in both directions, so
P(B given A) P(A) = P(A given B) P(B)
and dividing gives Bayes' theorem:
P(B given A) = P(B) P(A given B) / P(A)
P(A given B) = P(A) P(B given A) / P(B)
The bottom box computes each one from the other side, live, and it always lands on the same number as the picture above.
Should Huntington's Disease Remains the First Genetic Consideration in Adults Presenting with Combined Chorea and Ataxia in Resource-Limited Settings?
@MDCP_Journal
https://t.co/CHElhyIf8h
There is no such thing as safe gambling especially on the internet and advertising cues and sensitises the nucleus accumbens.
Some people are at greater risk but everyone is vulnerable to dependence and addiction
#dopaminedysregulationsyndrome
This important paper by Mitrotti and Valente in Movement Disorders Clinical Practice resonates with me because it reminds us that the value of genetic testing is not measured by how many mutations we discover, but by how we use that information to improve patients’ lives. In Parkinson’s disease, programs such as PD GENEration have demonstrated that meaningful genetic findings are not limited to younger patients or those with a family history. As we move toward genetically targeted treatments and clinical trials involving GBA1 and LRRK2, knowing a person's genetic status may increasingly influence care, counseling, and access to research. I particularly appreciate the authors’ SMART framework: Select, Match, Assess, React, and Track. It challenges us to move beyond simply ordering tests and toward building systems that translate genetic discoveries into meaningful clinical action. However, we must also address disparities in access, genetic counseling, and the interpretation of uncertain results. Genetic testing should not become another technology available only to the privileged few. For me, the central message is simple: the future of precision medicine in Parkinson’s disease is not about testing everyone indiscriminately or testing fewer people to save money. It is about testing intelligently, ensuring equitable access, and making every result count for patients and families.
https://t.co/m4o1HqgdSC
@hosungdetails@quetiapina600mg Ótima tabela.
O único cuidado é que está estranho, a relação morfina/metadona não é exatamente linear, existem alguns outros gráficos que mostram isso mais claro; além de muito cuidado nas formulações de liberação prolongada. Ótima explicação.
One study. One minute. Why it matters. 🧠
Dr. @GLanzinoNSGY highlights a study addressing a long-standing question about whether reduced blood flow caused by severe carotid artery narrowing contributes to cognitive problems that can be reversed by reopening the artery.
This is a super important study for our field of #autoimmune#neurology. Patients got much better in a disease which we often find hard to treat.
Fabulous news!!
But amidst the excitement, I hear a voice of reason say:
1. No control arm
2. A short (16 week) outcome after patients were given chemotherapy and steroids
This voice of reason aims to rationalise use of a potentially toxic therapies in our patients.
My conclusion: likely to be effective - perhaps very - but we lack conventional metrics to help us determine true efficacy
🔥Hot off the press for #ACR26 🔥
The @IgG4ward foundation guidelines on the treatment of IgG4-related disease
https://t.co/B3NKHxDKzK
Free to read on https://t.co/gt6JPgLHUG
📊 #RIMKLA-IgG was identified as a new biomarker of paraneoplastic neurological syndrome associated with cerebellar ataxia, hindbrain encephalitis, inflammatory cerebrospinal fluid, and frequent #SmallCellLungCancer. https://t.co/APBmdE24Hk